Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Comment by Actuarialon Mar 07, 2017 10:42am

209 Views

Post# 25943538

RE:RE: 12 month $1.50 valuation is very conservative

No way to release the interim results this month - the best COT can do is to release results of 4th cohort and start 5th cohort this month. I don't think $1.50 being very conservative either. Be aware of Zack analyst $1.50 target price conditional on COTI-2 successfully get FDA approval. Actually, if FDA indeed approved COTI-2, $10 per share would be a reasonable guess. It is a lottery, either go big or go home.

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?